Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 19;41:68. doi: 10.1186/s13046-022-02272-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — A Schematic diagram of the synthesis of Cu@CuOx-ECL1i, Cu@CuOx-ECL1i-Gem, and 64Cu-radiolabeled nanoparticles. B STEM of Cu@CuOx-ECL1i. C Number-average hydrodynamic diameter of Cu@CuOx-ECL1i. D In vitro TA-PEG-Gem release profiles of Cu@CuOx-ECL1i-Gem under physiological and acidic conditions. E Tumor growth (F) and mouse survival, curves of KI-implanted mice after being treated with Cu@CuOx-ECL1i-Gem, Cu@CuOx-ECL1i, Cu@CuOx-Gem, gemcitabine (7 mg/kg body weight, IV), gemcitabine (100 mg/kg body weight, IP), and saline. First treatment with Cu@CuOx-ECL1i-Gem started at 10 days’ post-tumor implantation. The Cu@CuOx-Gem and second treatment began at 7 days’ post-tumor implantation. G H&E staining of the tumor slices from mice treated with Cu@CuOx-ECL1i-Gem, H gemcitabine (100 mg/kg body weight), and (I) saline [129]